C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity

Science

Volumn 271, Issue 5247, 1996, Pages 348-350

  Dempsey, Paul W ^a   Allison, Michael E D ^a   Akkaraju, Srinivas ^b   Goodnow, Christopher C ^b   Fearon, Douglas T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; FREUND ADJUVANT; HEMOCYANIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; LYSOZYME;

ANIMAL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CBA MOUSE; CELL CULTURE; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; MOUSE; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD19; B-LYMPHOCYTES; COMPLEMENT C3D; FREUND'S ADJUVANT; HEMOCYANIN; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED CBA; MICE, TRANSGENIC; MURAMIDASE; RECEPTORS, COMPLEMENT 3D; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0030593030     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.271.5247.348     Document Type: Article

References (26)

1. C. A Janeway Jr, Immunol. Today 13, 11 (1992); P. Matzinger, Annu Rev. Immunol. 12, 991 (1994).
2. C. A Janeway Jr, Immunol. Today 13, 11 (1992); P. Matzinger, Annu Rev. Immunol. 12, 991 (1994).
3. D. T. Fearon and K F Austen, N. Engl! J. Med. 303, 259 (1980); H. J. Müller-Eberhard, Annu. Rev. Biochem. 57, 321 (1988).
4. D. T. Fearon and K F Austen, N. Engl! J. Med. 303, 259 (1980); H. J. Müller-Eberhard, Annu. Rev. Biochem. 57, 321 (1988).
5. D. T. Fearon and R H. Carter, Annu Rev. Immunol 13, 127 (1995); T. F. Tedder, L. J. Zhou, P Engel, Immunol. Today 15, 437 (1994)
6. D. T. Fearon and R H. Carter, Annu Rev. Immunol 13, 127 (1995); T. F. Tedder, L. J. Zhou, P Engel, Immunol. Today 15, 437 (1994)
7. R. C. Rickert, K Rajewsky, J. Roes, Nature 376, 352 (1995); P. Engel et al., Immunity 3, 39 (1995).
8. R. C. Rickert, K Rajewsky, J. Roes, Nature 376, 352 (1995); P. Engel et al., Immunity 3, 39 (1995).
9. M B. Pepys, J Exp. Med. 140, 126 (1974); B. Heyman, E. J. Wiersma, T. Kinoshita, ibid. 172, 665 (1990).
10. M B. Pepys, J Exp. Med. 140, 126 (1974); B. Heyman, E. J. Wiersma, T. Kinoshita, ibid. 172, 665 (1990).
11. T. Hebell, J. M Aheam, D. T. Fearon, Science 254, 102 (1991)
12. 3 was transiently expressed in COS cells. Recombinant proteins were purified by affinity chromatography on YL 1/2 antibody [R. H. Skinner et al , J Biol. Chem. 266, 14163 (1991)] and fractionation on Sephacryl S-200 (Pharmacia).
13. 3 was transiently expressed in COS cells. Recombinant proteins were purified by affinity chromatography on YL 1/2 antibody [R. H. Skinner et al , J Biol. Chem. 266, 14163 (1991)] and fractionation on Sephacryl S-200 (Pharmacia).
14. 3 was transiently expressed in COS cells. Recombinant proteins were purified by affinity chromatography on YL 1/2 antibody [R. H. Skinner et al , J Biol. Chem. 266, 14163 (1991)] and fractionation on Sephacryl S-200 (Pharmacia).
15. S. J Smith-Gill et al., J Immunol 128, 314 (1981).
16. 1 mice were produced by crossing MD4 with CBA/Ca (Harlan, Bicester, UK). Animal experiments were done according to procedures regulated under the Project License issued by the U.K Home Office
17. 125I bound to the cell pellet was determined.
18. 2+], were monitored by flow cytometric analysis (FACStar, Becton Dickinson) of PE-negative cells after addition of incremental concentrations of recombinant proteins.
19. T. Kinoshita et al., J. Immunol. 140, 3066 (1988).
20. 1·3 as antigens in the ELISA gave comparable results The data are represented as mean relative units (RU) + 1 SD based on a standard curve established with pooled sera from hyperimmunized mice.
21. 2 (CalTag).
22. D A Tuveson, R. H. Carter, S. P. Soltoff, D. T. Fearon, Science 260, 986 (1993).
23. W.-K Weng, L Jarvis, T W. LeBien, J. Biol. Chem. 269, 32514 (1994).
24. I. C. M MacLennan, Annu. Rev. Immunol 12, 117 (1994).
25. C C. Goodnow et al., Nature 334, 676 (1988).
26. We thank G Fey for the munne C3 complementary DNA, K. Drickarner for the dog pre-pro-insulin signal sequence, R. Smith for help in producing recombinant proteins, A. Venkitaraman for the A71d vector, and C Milstein for the YL 1/2 antibody. Supported by the Wellcome Trust (D.T.F. and P.W.D.), NIH grant A107247 (P.W.D), and the Medical Research Council (M E.D.A.), Howard Hughes Medical Institute (S.A. and C C.G.), and NIH grant Al19512 (C.C.G )